Our team

Founded by Jérôme Parc and Christophe Gaudin in 2016, Op2lysis has been created with the aim of developing the first medical treatment to reduce the severe sequelae that follow hemorrhagic stroke.

Op2lysis involves a team of 5 people with complementary skills and experiences including basic research and registration of pharmaceutical products, as well as support functions such as communication.




Parcq Jérôme
Co-founder, General Manager

Co-founder of Op2lysis, Jérôme has extensive experience in neurovascular research and stroke.

With a training in Agronomy Engineering and a PhD in Neurosciences, Jérôme completed his scientific background with a training in entrepreneurship at HEC, Paris (Challenge + program).

Over the past ten years, Jérôme has worked in the Inserm Unit (U1237), led by Professor Denis Vivien in Caen, to develop innovative therapeutic solutions to destroy blood clots. He is the co-inventor of Opt-PA, the formulated O2L-001 molecule.

Jérôme is in charge of the company’s operational and research activities.

Gaudin Christophe
Co-founder, President

Doctor specialist and co-founder of the company, Christophe has been in charge of cardiovascular and thrombosis development at Sanofi for the past 20 years.

With a MD degree, he has successfully developed and registered internationally many cardiovascular drugs, including antithrombotic products now widely used in coronary artery diseases, such as myocardial infarction.

Christophe is in charge of the management of the company, and foresees development activities.



Estelle Louet
Project Engineer, PhD student

An engineer at Op2lysis, Estelle is preparing a PhD within a Convention CIFRE that has been established with Inserm Unit U1237. Estelle holds a bachelor’s degree from the University of Freiburg and a master’s degree in medical biology from the University of Zurich, with a specialization in neuroscience.

Estelle’s mission is to establish the differentiating pharmacological characteristics of O2L-001.





Marie-Julie Guichard
Translational studies and regulatory affairs

In charge of translational and regulatory studies at Op2lysis, Marie-Julie has a dual Engineer-Chemist and Doctorate in Science training. After a Master 2, "Engineering for Health and Medicine", she continued her training with a PhD in biomedical and pharmaceutical sciences at the Catholic University of Louvain (Brussels, Belgium) thatshe obtained in April 2018. Her thesis focused on the pre-clinical development of an innovative mucolytic agent for cystic fibrosis.

During her training, Marie-Julie gained a one year experience in Cambridge, USA (Massachusetts) in a biotechnology company.
Marie-Julie is in charge of translational and regulatory studies for the development of O2L-001 to best ensure entry in clinical development, in compliance with international regulations.